Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
出版年份 2013 全文链接
标题
Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
作者
关键词
-
出版物
OncoImmunology
Volume 2, Issue 10, Pages e26527
出版商
Informa UK Limited
发表日期
2013-11-26
DOI
10.4161/onci.26527
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
- (2012) U. Bacher et al. BLOOD
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
- (2012) S. Gill et al. BLOOD
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural killer cells: a review of manufacturing and clinical utility
- (2012) Scott A. Koepsell et al. TRANSFUSION
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions
- (2012) Hans Klingemann et al. TRANSFUSION
- Tumor Induced Inactivation of Natural Killer Cell Cytotoxic Function; Implication in Growth, Expansion and Differentiation of Cancer Stem Cells
- (2012) Anahid Jewett et al. Journal of Cancer
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
- (2011) D V Tassev et al. CANCER GENE THERAPY
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
- (2011) Carlos A Ramos et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
- (2011) Kory L. Alderson et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
- (2011) Ruth Esser et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
- (2011) Laurent Boissel et al. LEUKEMIA & LYMPHOMA
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)
- (2010) Amanda K. Purdy et al. CANCER BIOLOGY & THERAPY
- Ex-vivo expansion of NK cells: What is the priority - high yield or high purity?
- (2010) Maria Berg et al. CYTOTHERAPY
- Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia
- (2009) James Weitzman et al. LEUKEMIA & LYMPHOMA
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started